The Nogareda brothers’ commitment to Spain’s coronavirus vaccine

Hipra just started Clinical trials to assess immune response The vaccine has been adapted to new variants of Covid-19. The Catalan lab has received all the authorizations from Spain, the EU and even the World Health Organization to sell its coronavirus vaccine, but so far, It has only succeeded in delivering 3.2 million doses of vaccine to the Spanish government, His only client.

The Shipra booster vaccine was distributed to health services across Spain last summer. However, as confirmed by this outlet, people over 60 who are re-vaccinated this autumn in primary care centers in Catalonia are best served with the Pfizer/BioNTech dose. at present, Hipra vaccine falls short of commercial expectations Sales have fallen far short of maximum production capacity of 250 million doses a year amid doubts about its adaptation to new variants of the virus and competition from the global giants that control the market. But Shipra didn’t give up: Continue testing to adapt their sera to emerging mutations and even, They work on a new vaccine against respiratory syncytial virus (VRS). This can lead to bronchitis and pneumonia, especially in infants and minors.

Hipra is a laboratory with more than 50 years of experience in the field of animal health. During the epidemic, Three years ago, he first entered the field of human health care. In 2020, they were responsible for the PCR testing at the Girona Health Center. Subsequently, its technical staff believed that obtaining a new coronavirus vaccine was feasible.A year later, they acquired the biotech startup Good intestines

founded by medical researchers Mariana Serra-Pagos Specializing in diagnostic testing for intestinal diseases.

second generation

This commitment to human health is led by the second generation of the Nogareda family. Since his father took over as president in 2007, David Nogareda EstivelThe 58-year-old company is committed to international expansion (it has 50 subsidiaries abroad and operates in 100 countries), focusing on vaccines for farm animals (it has risen to sixth place in the world) and, more recently, human vaccines. It is curious that a trained veterinarian who heads United Animal Pharmaceuticals would dare to develop a vaccine for humans.

David Nogareda always errs on the side of caution. He does not give interviews to the media and is not active on social networks. Before they announced the preparation of the coronavirus vaccine, only one photo of him could be found, and it was in the company of Artur Mas, the same photo he took with the then government president in Amer in 2011 Corresponding to the inauguration ceremony of the new plant in Shipra, Rhone). Since then, Pedro Sánchez’s picture has appeared during his two visits to the facilities (in 2021 and 2023, above) and last year when Father Aragonés presented Shipra with the Cross of St. George.

You can also find some pictures of him if you search classic racing, one of his hobbies. He raced in Monte Carlo or Le Mans in a 1966 Porsche 906 (pictured above). Despite his own judgment, he participated in public events and business associations.one of them is female catHe served as vice president of the organization during the leadership of Pau Relat.

Among the four Nogareda Estille brothers—david, maria del mar, Arnau and milena-, The first three hold senior management positions and are members of Hipra’s board of directors. Representing their respective properties: Clau de Safir (David), Clau de Rubí (Mar) and Clau d’Atzabeja (Arnau). The sources consulted made it clear that Milena also works for Hipra and is in the capital through the company Clau de Maragda, but is not a board member.

Maria del Mar Nogareda

57 years old, Serves as Vice President and General Manager of Hipra. Business graduate, Its name appears in dozens of business subsidiaries around the world. He is a member of several Girona entities, such as the advisory board of the Forum Carlemany Business Association or of the Cercle de La Ciutat Invisible (the intersection of business and cultural circles that promotes the Montaña Alta Festival).He is also a member of the company’s board of directors Princess of Girona Foundationwhose honorary chairman is the King Philip VI and princess Eleanor.

Arno Nogareda He also serves as Vice President and General Manager of Hipra. Member of the Board of Directors of Fundació per la Creativació, an entity from Girona dedicated to promoting a new generation of innovation. Passionate about cycling.

Founder

his father, Joan Nogareda Giuffre (Olot, 1934), Remains as Honorary Chairman. He graduated in Chemistry (University of Barcelona), Veterinary Medicine and Pharmacy (the last two, from Universidad Complutense).Accompanied by his brother Ernesto, brother-in-law Lluís Tremoleda (a pharmacist from Olot) and Manuel Sobrino (a Madrid laboratory technician stationed in the Garrotxa region) Laboratorios Sobrino founded in 1954. The first goal is to produce serum against African swine fever. They then brought the first vaccines against bird diseases to market.

In the early seventies he left Laboratorios Sobrino in Vall de Bianya (Girona), which in the following decades was run by the North American multinationals Fort Dodge, Pfizer and now Zoetis controls.

As Franco’s government created difficulties in setting up new pharmaceutical companies, In 1971, Joan Nogareda acquired the Madrid company Laboratorios de Sanidad Veterinaria Hipra. Due to financial difficulties, the company was on the verge of disappearing. The name, which remains in use today, is derived from the combination of the first syllables of the surnames of its first owner, military veterinarian Hidalgo and Prado. Two years later, in 1973, he rebuilt Hipra in Amer Participation of other investors. In the early nineties, when some shareholders proposed selling to a multinational company in the industry, Nogareda bought their shares and became the majority shareholder. In 2007, he handed over the presidency to his son David.

Joan Nogareda Gifré is co-founder of the National Association of Scientific Pig Farming (Anapoque) and served as Director General of the International Swine Veterinary Society (1986-1988). He remains a member of the Academy of Veterinary Sciences of Catalonia.

In addition to the three Nogareda brothers, Board of Directors Merged executives from the same company Elia Toroela (Executive Vice President, Research and Development) and independent directors, e.g. Alfredo Blue (co-founder and CEO of Sherpa Venture Capital Fund, although the firm is not a partner) or Richard Rector – Former Managing Director of Dogi, now Nextil, where he is also a Director).

Hipra’s turnover last year was close to 397 million eurosan increase of 14% over the previous year, thanks to “Good performance from the animal health sectorThe company reported profits of 55.7 million euros last July, up 11%, although EBITDA fell 17% to 70.3 million euros, due to investments in research and development to secure a Covid vaccine. According to their figures, they have invested 83 million euros in purchasing the vaccine and building a project called Campus Hipra in Aiguaviva (Girones province), which is expected to be completed in 2026. The sale of 3.2 million doses of the vaccine will provide them with 31 million euros, which will be calculated into the 2023 financial year. However, so far, this vaccine has not brought the expected profitability.